Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023).

Author:

Rutgers Emiel J.1,Donker Mila2,Straver Marieke Evelien2,Meijnen Philip2,Van De Velde Cornelis J. H.3,Mansel Robert E.4,Westenberg Helen5,Orzalesi Lorenzo6,Bouma Willem H.7,van der Mijle Huub8,Nieuwenhuijzen Grard A. P.9,Veltkamp Sanne C.10,Slaets Leen11,Messina Carlo G. M.12,Duez Nicole J.11,Hurkmans Coen13,Bogaerts Jan11,van Tienhoven Geertjan14

Affiliation:

1. Netherlands Cancer Institute, Amsterdam, Netherlands

2. NKI-AVL, Amsterdam, Netherlands

3. Leiden University Medical Center, Department of Surgery, Leiden, Netherlands

4. Cardiff University, Cardiff, United Kingdom

5. Institute for Radiation Oncology Arnhem, Arnhem, Netherlands

6. Breast Unit, Careggi University Hospital, Florence, Italy

7. Department of Surgery, Gelre Hospital, Apeldoorn, Netherlands

8. Department of Surgery, Nij Smellinghe Hospital, Drachten, Netherlands

9. Department of Surgery, Catharina Hospital, Eindhoven, Netherlands

10. Department of Surgery, Amstelland Hospital, Amstelveen, Netherlands

11. European Organisation for Research and Treatment of Cancer, Brussels, Belgium

12. EORTC Headquarters, Brussels, Belgium

13. Department of Radiation Oncology, Catherina Hospital, Eindhoven, Netherlands

14. Department of Radiation Oncology, Academic Medical Centre, Amsterdam, Netherlands

Abstract

LBA1001 Background: Sentinel node biopsy (SNB) is standard in assessing axillary lymph node status for cN0 breast cancer patients. In case of a positive SNB, if treatment is advised, axillary lymph node dissection (ALND) is the current standard. Although ALND provides excellent regional control, it may give harmful side effects. Axillary radiotherapy (ART) instead of ALND was hypothesized to provide comparable regional control and less side effects. Methods: From 2001 to 2010, patients with cT1E2N0 primary breast cancer were enrolled in the EORTC phase III non-inferiority AMAROS trial. Patients were randomized between ALND and ART in case of a positive SNB. Primary endpoint was 5-year axillary recurrence rate. Secondary endpoints were overall survival (OS), disease-free survival (DFS), quality of life (QOL), shoulder movement and lymphedema at 1 and 5 years. Results: Of the 4,806 patients entered in the trial, 744 in the ALND-arm and 681 in the ART-arm had a positive SNB, 60% with a macrometastasis. The two treatment-arms were comparable regarding age, tumor size, grade, tumor type, and adjuvant systemic treatment. With a median follow up of 6.1 years, the 5-year axillary recurrence rate after a positive SNB was 0.54% (4/744) after ALND versus 1.03% (7/681) after ART. The planned non-inferiority test was underpowered because of the unexpectedly low number of events. The axillary recurrence rate after a negative SNB was 0.8% (25/3131). There were no significant differences between treatment arms regarding OS (5 yr estimates: 93.27% ALND, 92.52% ART, p=0.3386) and DFS (5 yr estimates: 86.90% ALND, 82.65% ART, p=0.1788). Lymphedema was found significantly more often after ALND (1yr: 40% ALND, 22% ART, p<0.0001 and 5yr: 28% ALND, 14% ART, p<0.0001). There was a nonsignificant trend toward more early shoulder movement impairment after ART. These findings were compatible with a trend in two QOL items in the arm symptom scale: swelling (ART better) and movement (ALND better). There were no other differences in QOL. Conclusion: ALND and ART after a positive SNB provide excellent and comparable regional control. ART reduces the risk of short-term and long-term lymphedema compared to ALND. Clinical trial information: NCT00014612.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 60 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3